Trial Profile
A Study Comparing Effect Of Direct Acting Antiviral (DAA) Regimen And Interferon-a/Ribavirin Therapy On Transcriptional Changes In Patients With Chronic Hepatitis-C Infection.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jan 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Pharmacodynamics; Therapeutic Use
- 26 Jan 2017 New trial record